Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, including stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Study: High blood sugar is linked with PAH adverse outcomes

Indicators of high blood sugar levels, particularly stress hyperglycemia ratio (SHR), may predict clinical worsening in people with idiopathic pulmonary arterial hypertension, a study in China indicates. Clinical worsening was defined as the first occurrence of lung transplant, being rehospitalized due to heart failure, or death from any cause.

Awareness campaign aims to improve PAH diagnosis, treatment

A new educational campaign aims to raise awareness of pulmonary arterial hypertension (PAH) symptoms, with the goal of accelerating diagnosis and improving treatment. The American Lung Association campaign has the support of Merck, which markets Winrevair (sotatercept), a medication approved this year in the U.S. and…

New INOmax inhaled nitric oxide device now available to US NICUs

A new device to deliver inhaled nitric oxide gas to newborns with pulmonary hypertension (PH), is now available for use in hospital neonatal intensive care units (NICUs) across the U.S. The rollout follows recent approval from the U.S. Food and Drug Administration of the next-generation device, the INOmax…

Tiny vesicles may reduce vascular remodeling in PH: Rat study

Exosomes, a type of small vesicle released by mesenchymal stem cells (MSCs), helped reduce vascular remodeling and ease pulmonary hypertension (PH) symptoms in a rat model of the disease, a study found. Exosome effects were tied to a modulation of the NF-kB/BMP pathway involved in vascular remodeling, a set…

Taking selenium supplements may help prevent PAH: Study

The use of selenium supplements — an essential mineral naturally present in many foods and added to others — reduced blood vessel remodeling, a hallmark of pulmonary arterial hypertension (PAH), in the lung, according to a new study. Selinium has antioxidant properties and may help protect cells from damage.

PAH therapy reverses blood vessel remodeling in preclinical model

Cereno Scientific’s investigational therapy CS014 was found to reverse remodeling, meaning alterations in structure and arrangement, of pulmonary arteries in a preclinical model of pulmonary arterial hypertension (PAH). According to the company, the new preclinical data “provide the most compelling evidence to date that CS014 offers a…

Riociguat found safe, effective for PAH with coexisting conditions

Treatment with Adempas (riociguat) is generally safe and effective for people with pulmonary arterial hypertension (PAH) and coexisting cardiometabolic conditions, or those that affect the heart and metabolism, according to a pooled analysis of clinical trials. “Efficacy and risk assessment results suggest that [Adempas] can be beneficial for…

CS1 receives orphan medicinal product status for PAH in Europe

The European Commission has granted orphan medicinal product designation to Cereno Scientific’s CS1 for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications for life-threatening or chronically debilitating diseases, affecting up to five per 10,000 individuals in the European Union (EU), or…

European Commission approves Winrevair to treat PAH in adults

Winrevair (sotatercept-csrk), Merck’s injection therapy for adults with pulmonary arterial hypertension (PAH), has been approved in the European Union, as well as in Iceland, Liechtenstein, and Norway. The approval from the European Commission specifically covers Winrevair when used in combination with other PAH therapies to improve…